Premium
A molecular analysis and clinical follow up: a strategy for hereditary cancer prevention
Author(s) -
Soares Barbara Luisa,
Santos Luciana Lara,
Lima Karine Evangelista,
Mayrink Luiz Henrique,
Valentin Aline Angélica Souza,
Oliveira Eneida Santos,
Lemos Sara,
Lopes Debora Oliveira,
Azevedo Barbosa Leandro,
Rodrigues Angelica
Publication year - 2013
Publication title -
the faseb journal
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.709
H-Index - 277
eISSN - 1530-6860
pISSN - 0892-6638
DOI - 10.1096/fasebj.27.1_supplement.608.1
Subject(s) - hereditary cancer , medicine , cancer , family history , genetic counseling , incidence (geometry) , general partnership , genetics , biology , breast cancer , physics , finance , optics , economics
According to the Brazilian National Institute, the incidence of cancer in Minas Gerais state, Brazil, is approximately 50.000 new cases per year. 5–10% of these cases are associated with hereditary predisposition. This project is a partnership among the public Cancer Hospital of Divinopolis, Federal University of São João del Rei and a Non Governamental Organization against Cancer. The objective is to structure a center for familial cancer control based in clinical and molecular analysis. Patients with clinical suspected familial cancer are assisted, familial history is collected and heredograms are made in Progeny software. Risk assessment is done and families who fill clinical criteria for hereditary cancer are advised about the importance of close follow‐up. After consent, 5 ml of blood are collected for molecular studies. Specific genes related to the suspected syndrome are screened for mutations. The techniques used are High Resolution Melting (HRM) and Sequencing. From January 2011 to date, 19 families were registered for different cancer familial syndromes. At this moment, different genes have been analyzed by HRM and are being sequenced. This study will help to identify the individuals with real risk, so that genetic counseling can be done. The partnership is a promissing solution for the establishment of clinical‐molecular projects in regions with limited economic resources. Support: CNPq and FAPEMIG.